332 participants
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-05
- Start Date:
- 2022-03-07
- Completion:
- 2031-02-10
Conditions
- Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
- DRUG
No Results Yet